ZLAB – Zai Lab Limited

ZLAB — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.42

Margin Of Safety %

Put/Call OI Ratio

2.74

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.29

EPS This/Next Y

0.5

Price

21.02

Target Price

33.26

Analyst Recom

1.24

Performance Q

16.09

Upside

-368.3%

Beta

0.77

Ticker: ZLAB

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ZLAB	19.17	1.75	0.00	5736
2026-03-10	ZLAB	19.5	1.74	0.08	5739
2026-03-11	ZLAB	19.11	1.71	1.67	5777
2026-03-12	ZLAB	18.89	1.71	999.99	5777
2026-03-13	ZLAB	18.87	1.71	999.99	5777
2026-03-17	ZLAB	19.04	1.97	13.33	6335
2026-03-18	ZLAB	18.82	1.94	3.29	6252
2026-03-19	ZLAB	18.61	1.89	2.60	6141
2026-03-20	ZLAB	18.08	1.90	0.83	6135
2026-03-23	ZLAB	17.64	3.63	1.20	4431
2026-03-24	ZLAB	17.48	3.60	1.00	4460
2026-03-25	ZLAB	18.29	3.58	0.23	4479
2026-03-26	ZLAB	17.57	3.57	1.20	4483
2026-03-27	ZLAB	18.01	3.44	0.53	4582
2026-03-30	ZLAB	17.85	3.46	0.40	4590
2026-03-31	ZLAB	18.81	3.45	6.00	4595
2026-04-01	ZLAB	20.33	3.45	0.06	4589
2026-04-02	ZLAB	20.43	3.06	0.03	4727
2026-04-06	ZLAB	20.52	2.76	0.00	4852
2026-04-07	ZLAB	21.03	2.74	3.62	4861
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ZLAB	19.12	-3.6	-	-1.91
2026-03-10	ZLAB	19.47	-3.6	-	-1.91
2026-03-11	ZLAB	19.08	-3.6	-	-1.91
2026-03-12	ZLAB	18.88	-3.6	-	-1.91
2026-03-13	ZLAB	18.34	-3.6	-	-1.91
2026-03-17	ZLAB	19.03	-3.6	-	-1.91
2026-03-18	ZLAB	18.82	-3.6	-	-1.91
2026-03-19	ZLAB	18.61	-3.6	-	-1.91
2026-03-20	ZLAB	18.08	-3.6	-	-1.89
2026-03-23	ZLAB	17.66	-3.6	-	-1.89
2026-03-24	ZLAB	17.49	-3.6	-	-1.89
2026-03-25	ZLAB	18.30	-3.6	-	-1.89
2026-03-26	ZLAB	17.53	-3.6	-	-1.89
2026-03-27	ZLAB	18.00	-3.6	-	-1.89
2026-03-30	ZLAB	17.86	-3.6	-	-1.89
2026-03-31	ZLAB	18.82	-3.6	-	-1.89
2026-04-01	ZLAB	20.34	-3.6	-	-1.89
2026-04-02	ZLAB	20.41	-3.6	-	-1.89
2026-04-06	ZLAB	20.52	-3.6	-	-1.89
2026-04-07	ZLAB	21.02	-3.6	-	-1.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ZLAB	-7.30	-9.48	3.06
2026-03-10	ZLAB	-11.60	-9.48	3.06
2026-03-11	ZLAB	-11.60	-9.48	3.45
2026-03-12	ZLAB	-11.64	-9.48	3.45
2026-03-13	ZLAB	-12.05	-9.48	3.45
2026-03-17	ZLAB	-12.37	-9.72	3.45
2026-03-18	ZLAB	-12.37	-9.72	3.45
2026-03-19	ZLAB	-12.30	-9.72	3.45
2026-03-20	ZLAB	-12.30	-9.72	3.45
2026-03-23	ZLAB	-12.30	-9.42	3.45
2026-03-24	ZLAB	-12.30	-9.42	3.45
2026-03-25	ZLAB	-12.30	-9.42	4.44
2026-03-26	ZLAB	-12.30	-9.42	4.44
2026-03-27	ZLAB	-12.30	-9.42	4.44
2026-03-30	ZLAB	-12.30	-9.86	4.42
2026-03-31	ZLAB	-12.25	-9.86	4.42
2026-04-01	ZLAB	-12.25	-9.86	4.42
2026-04-02	ZLAB	-12.25	-9.86	4.42
2026-04-06	ZLAB	-13.59	-9.89	4.42
2026-04-07	ZLAB	-13.59	-9.89	4.42
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.46

Avg. EPS Est. Current Quarter

-0.47

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-13.59

Institutional Transactions

-9.89

Beta

0.77

Average Sales Estimate Current Quarter

117

Average Sales Estimate Next Quarter

122

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.5

Max Drawdown 5-Year %

-92.4

Target Price

33.26

P/E

Forward P/E

PEG

P/S

5.13

P/B

3.25

P/Free Cash Flow

EPS

-1.61

Average EPS Est. Cur. Y

-1.89

EPS Next Y. (Est.)

-1.4

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-38.15

Relative Volume

0.64

Return on Equity vs Sector %

-52

Return on Equity vs Industry %

-35.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.78

EBIT Estimation

◆ ZLAB Healthcare

$21.00

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

6/25

Volume

9/15

Valuation

12/20

TP/AR

2/10

Options

2/10

RSI

65.9

Range 1M

100%

Sup Dist

3.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

17/30

Estimates

2/20

Inst/Vol

2/15

Options

3/10

EPS Yr

-9.7%

EPS NY

31.4%

52W%

17.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +58.4% upside

Quality

5/30

Valuation

12/30

Growth

11/25

Stability

6/10

LT Trend

3/5

Upside

+58.4%

Quality

Zai Lab Limited

Sector: Healthcare

Industry: Biotechnology

Employees: 1784

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin. The company was incorporated in 2013 and is based in Pudong, China.

ZLAB

Latest News

—

Caricamento notizie per ZLAB…

stock quote shares ZLAB – Zai Lab Limited Stock Price stock today

news today ZLAB – Zai Lab Limited stock forecast ,stock prediction 2023 2024 2025

marketwatch ZLAB – Zai Lab Limited yahoo finance google finance

stock history ZLAB – Zai Lab Limited invest stock market

stock prices ZLAB premarket after hours

ticker ZLAB fair value insiders trading

ZLAB – Zai Lab Limited

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ZLAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y